A 25-year-old woman with severe allergic asthma and frequent exacerbations despite high-dose ICS+LABA, positive skin prick tests, serum IgE 350 IU/mL, and blood eosinophils 600/µL. Which biologic targets the IgE-mediated pathway to reduce exacerbations?

• A Mepolizumab
• B Benralizumab
• C Dupilumab
• D Omalizumab ✓

Explanation

Omalizumab is a recombinant humanized monoclonal antibody that binds free IgE, preventing interaction with mast cells and basophils. It is indicated in moderate-to-severe allergic asthma with elevated IgE. Mepolizumab and benralizumab target IL-5/eosinophils. Dupilumab blocks IL-4Rα, inhibiting both IL-4 and IL-13.

Reference: Harrison's Principles of Internal Medicine, 21st ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.